JP2024515545A5 - - Google Patents
Info
- Publication number
- JP2024515545A5 JP2024515545A5 JP2023561276A JP2023561276A JP2024515545A5 JP 2024515545 A5 JP2024515545 A5 JP 2024515545A5 JP 2023561276 A JP2023561276 A JP 2023561276A JP 2023561276 A JP2023561276 A JP 2023561276A JP 2024515545 A5 JP2024515545 A5 JP 2024515545A5
- Authority
- JP
- Japan
- Prior art keywords
- methyl
- piperidine
- oxoisoindorin
- dione
- pyridine
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163170865P | 2021-04-05 | 2021-04-05 | |
| US63/170,865 | 2021-04-05 | ||
| US202163189318P | 2021-05-17 | 2021-05-17 | |
| US63/189,318 | 2021-05-17 | ||
| PCT/US2022/023236 WO2022216573A1 (en) | 2021-04-05 | 2022-04-04 | Pyridinyl substituted oxoisoindoline compounds for the treatment of cancer |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2024515545A JP2024515545A (ja) | 2024-04-10 |
| JP2024515545A5 true JP2024515545A5 (enExample) | 2025-04-04 |
Family
ID=83546459
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023561276A Pending JP2024515545A (ja) | 2021-04-05 | 2022-04-04 | がん治療のためのピリジニル置換オキソイソインドリン化合物 |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20250346574A1 (enExample) |
| EP (1) | EP4320125A1 (enExample) |
| JP (1) | JP2024515545A (enExample) |
| KR (1) | KR20230167067A (enExample) |
| AU (1) | AU2022253450A1 (enExample) |
| BR (1) | BR112023020410A2 (enExample) |
| CA (1) | CA3214240A1 (enExample) |
| IL (1) | IL307338A (enExample) |
| MX (1) | MX2023011408A (enExample) |
| WO (1) | WO2022216573A1 (enExample) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20240327381A1 (en) * | 2023-02-08 | 2024-10-03 | Celgene Corporation | Compounds and Compositions for Selective Degradation of Engineered Proteins |
| AU2024285766A1 (en) | 2023-06-07 | 2026-01-08 | Bristol-Myers Squibb Company | Spirocyclic substituted oxoisoindolinyl piperidine-2,6-dione compound |
| WO2024263853A1 (en) | 2023-06-23 | 2024-12-26 | Bristol-Myers Squibb Company | Substituted oxoisoindolinyl piperidine-2,6-dione compound as anticancer agent |
| WO2025064197A1 (en) | 2023-09-02 | 2025-03-27 | Bristol-Myers Squibb Company | Substituted azetidinyl oxoisoindolinyl piperidine-2,6-dione compounds |
| WO2025226767A1 (en) | 2024-04-24 | 2025-10-30 | Bristol-Myers Squibb Company | Substituted 3-(5-(6-aminopyridin-2-yl)-4-fluoro-1-oxoisoindolin-2-yl)piperidine-2,6-dione compounds for use in the treatment of cancer |
| US12565492B2 (en) | 2024-08-09 | 2026-03-03 | Triana Biomedicines, Inc. | Anaplastic Lymphoma Kinase (ALK) degraders and uses thereof |
Family Cites Families (39)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI380996B (zh) | 2004-09-17 | 2013-01-01 | Hoffmann La Roche | 抗ｏｘ４０ｌ抗體 |
| PT2343320T (pt) | 2005-03-25 | 2018-01-23 | Gitr Inc | Anticorpos anti-gitr e as suas utilizações |
| PL1879573T3 (pl) | 2005-05-10 | 2013-05-31 | Incyte Holdings Corp | Modulatory 2,3-dioksygenazy indoloaminy i sposoby ich zastosowania |
| PT1907424E (pt) | 2005-07-01 | 2015-10-09 | Squibb & Sons Llc | Anticorpos monoclonais humanos para o ligando 1 de morte programada (pd-l1) |
| US8450351B2 (en) | 2005-12-20 | 2013-05-28 | Incyte Corporation | N-hydroxyamidinoheterocycles as modulators of indoleamine 2,3-dioxygenase |
| WO2008036642A2 (en) | 2006-09-19 | 2008-03-27 | Incyte Corporation | N-hydroxyamidinoheterocycles as modulators of indoleamine 2,3-dioxygenase |
| CL2007002650A1 (es) | 2006-09-19 | 2008-02-08 | Incyte Corp | Compuestos derivados de heterociclo n-hidroxiamino; composicion farmaceutica, util para tratar cancer, infecciones virales y desordenes neurodegenerativos entre otras. |
| EP1987839A1 (en) | 2007-04-30 | 2008-11-05 | I.N.S.E.R.M. Institut National de la Sante et de la Recherche Medicale | Cytotoxic anti-LAG-3 monoclonal antibody and its use in the treatment or prevention of organ transplant rejection and autoimmune disease |
| US8591886B2 (en) | 2007-07-12 | 2013-11-26 | Gitr, Inc. | Combination therapies employing GITR binding molecules |
| EP2044949A1 (en) | 2007-10-05 | 2009-04-08 | Immutep | Use of recombinant lag-3 or the derivatives thereof for eliciting monocyte immune response |
| US10047066B2 (en) | 2007-11-30 | 2018-08-14 | Newlink Genetics Corporation | IDO inhibitors |
| WO2009156652A1 (fr) | 2008-05-29 | 2009-12-30 | Saint-Gobain Centre De Recherches Et D'etudes Europeen | Structure en nid d'abeille a base de titanate d'aluminium |
| AR072999A1 (es) | 2008-08-11 | 2010-10-06 | Medarex Inc | Anticuerpos humanos que se unen al gen 3 de activacion linfocitaria (lag-3) y los usos de estos |
| EP3255060A1 (en) | 2008-12-09 | 2017-12-13 | F. Hoffmann-La Roche AG | Anti-pd-l1 antibodies and their use to enhance t-cell function |
| KR101790802B1 (ko) | 2009-09-03 | 2017-10-27 | 머크 샤프 앤드 돔 코포레이션 | 항-ｇｉｔｒ 항체 |
| EP2493862B1 (en) | 2009-10-28 | 2016-10-05 | Newlink Genetics Corporation | Imidazole derivatives as ido inhibitors |
| ES2722300T3 (es) | 2009-12-10 | 2019-08-09 | Hoffmann La Roche | Anticuerpos que se unen preferentemente al dominio extracelular 4 de CSF1R y su uso |
| EP2542256B1 (en) | 2010-03-04 | 2019-05-22 | MacroGenics, Inc. | Antibodies reactive with b7-h3, immunologically active fragments thereof and uses thereof |
| US9169323B2 (en) | 2010-03-05 | 2015-10-27 | Hoffmann-La Roche Inc. | Antibodies against human CSF-1R |
| JP5989547B2 (ja) | 2010-03-05 | 2016-09-07 | エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト | ヒトｃｓｆ−１ｒに対する抗体及びその使用 |
| HRP20190047T1 (hr) | 2010-05-04 | 2019-02-22 | Five Prime Therapeutics, Inc. | Protutijela koja se vežu na csf1r |
| MX337040B (es) | 2010-09-09 | 2016-02-09 | Pfizer | Moleculas de union a 4-1bb. |
| NO2694640T3 (enExample) | 2011-04-15 | 2018-03-17 | ||
| JP6072771B2 (ja) | 2011-04-20 | 2017-02-01 | メディミューン，エルエルシー | Ｂ７−ｈ１およびｐｄ−１に結合する抗体およびその他の分子 |
| KR101764096B1 (ko) | 2011-11-28 | 2017-08-02 | 메르크 파텐트 게엠베하 | 항-ｐｄ-ｌ1 항체 및 그의 용도 |
| RU2658603C2 (ru) | 2011-12-15 | 2018-06-21 | Ф.Хоффманн-Ля Рош Аг | Антитела против человеческого csf-1r и их применения |
| KR20140127855A (ko) | 2012-02-06 | 2014-11-04 | 제넨테크, 인크. | Csf1r 억제제를 사용하는 조성물 및 방법 |
| AR090263A1 (es) | 2012-03-08 | 2014-10-29 | Hoffmann La Roche | Terapia combinada de anticuerpos contra el csf-1r humano y las utilizaciones de la misma |
| RU2670743C9 (ru) | 2012-05-11 | 2018-12-19 | Файв Прайм Терапьютикс, Инк. | Способы лечения состояний антителами, которые связывают рецептор колониестимулирующего фактора 1 (csf1r) |
| UY34887A (es) | 2012-07-02 | 2013-12-31 | Bristol Myers Squibb Company Una Corporacion Del Estado De Delaware | Optimización de anticuerpos que se fijan al gen de activación de linfocitos 3 (lag-3) y sus usos |
| CN107759690A (zh) | 2012-08-31 | 2018-03-06 | 戊瑞治疗有限公司 | 用结合群落刺激因子1受体(csf1r)的抗体治疗病状的方法 |
| BR112019011200B1 (pt) | 2016-12-01 | 2021-12-28 | Arvinas Operations, Inc | Derivados de tetrahidronaftaleno e tetrahidroisoquinolina como degradadores do receptor de estrogênio |
| AU2018300150A1 (en) | 2017-07-11 | 2020-01-30 | Vertex Pharmaceuticals Incorporated | Carboxamides as modulators of sodium channels |
| EP3773576A4 (en) * | 2018-03-26 | 2021-12-29 | C4 Therapeutics, Inc. | Cereblon binders for the degradation of ikaros |
| CA3123519A1 (en) * | 2019-02-15 | 2020-08-20 | Novartis Ag | Substituted 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof |
| CN113490528B (zh) * | 2019-02-15 | 2024-12-03 | 诺华股份有限公司 | 3-(1-氧代-5-(哌啶-4-基)异吲哚啉-2-基)哌啶-2,6-二酮衍生物及其用途 |
| JP2022533260A (ja) * | 2019-05-24 | 2022-07-21 | バイオセリックス， インコーポレイテッド | タンパク質を標的とする化合物及びその医薬組成物並びにそれらの治療的応用 |
| JP7629459B2 (ja) * | 2019-11-19 | 2025-02-13 | ブリストル－マイヤーズ スクイブ カンパニー | Ｈｅｌｉｏｓタンパク質の阻害剤として有用な化合物 |
| JP7819176B2 (ja) * | 2020-08-03 | 2026-02-24 | ノバルティス アーゲー | ヘテロアリール置換３－（１－オキソイソインドリン－２－イル）ピペリジン－２，６－ジオン誘導体及びその使用 |
-
2022
- 2022-04-04 AU AU2022253450A patent/AU2022253450A1/en active Pending
- 2022-04-04 WO PCT/US2022/023236 patent/WO2022216573A1/en not_active Ceased
- 2022-04-04 BR BR112023020410A patent/BR112023020410A2/pt unknown
- 2022-04-04 US US18/553,999 patent/US20250346574A1/en active Pending
- 2022-04-04 EP EP22719432.1A patent/EP4320125A1/en active Pending
- 2022-04-04 KR KR1020237037710A patent/KR20230167067A/ko active Pending
- 2022-04-04 MX MX2023011408A patent/MX2023011408A/es unknown
- 2022-04-04 IL IL307338A patent/IL307338A/en unknown
- 2022-04-04 JP JP2023561276A patent/JP2024515545A/ja active Pending
- 2022-04-04 CA CA3214240A patent/CA3214240A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2024515545A5 (enExample) | ||
| ES2548532T3 (es) | Compuestos de pirrolopirimidina como inhibidores de CDK4/6 | |
| JP2022504936A5 (enExample) | ||
| TWI874541B (zh) | Egfr抑制劑 | |
| JP6895439B2 (ja) | ＩＲＡＫ４調節因子としてのピラゾロ［１，５ａ］ピリミジン誘導体 | |
| ES2898206T3 (es) | Compuestos heterocíclicos que tienen actividad como moduladores de los receptores muscarínicos M1 y/o M4 en el tratamiento de enfermedades y dolores del SNC | |
| BR112021001292A2 (pt) | compostos heterobicíclicos para inibir a atividade de shp2 | |
| JP7344125B2 (ja) | 細菌感染の治療及び予防のための新規ピリド［２，３－ｂ］インドール化合物 | |
| JP2014506929A5 (enExample) | ||
| CA2629777A1 (en) | Spirocyclic compounds as hdac inhibitors | |
| RU2020129785A (ru) | Фармацевтические производные 6,5-гетеробициклического кольца | |
| RU2016135637A (ru) | 6-гетероарилокси- и 6-арилоксихинолин-2-карбоксамиды и их применение | |
| JP2018530557A5 (enExample) | ||
| JP2017531672A5 (enExample) | ||
| JP2023549123A5 (enExample) | ||
| EP4419529A1 (en) | Covalent egfr inhibitors and methods of use thereof | |
| WO2024254532A1 (en) | Bifunctional azines conjogates as selective degraders of smarca2 and therapeutic uses thereof | |
| RU2780532C1 (ru) | Ингибиторы протеинтирозинфосфатазы | |
| US20260035387A1 (en) | Compounds for treating huntington's disease | |
| EP4583977A1 (en) | Heterocyclic derivatives as janus kinase inhibitors | |
| WO2025165930A1 (en) | Methods for treating spinal muscular atrophy | |
| TH2401004994A (th) | อิมิดาโซลมาโครไซเคิลสำหรับการบำบัดของโรคภูมิต้านต่อตนเอง | |
| HUE025203T2 (en) | CDK4 / 6 inhibitor pyrrolopyrimidine compounds |